The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027

全身性エリテマトーデス(SLE)治療薬の世界市場予測

◆タイトル:The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027
◆商品コード:VGAIN705043
◆調査・発行会社:visiongain
◆発行日:2017年5月
◆ページ数:152
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名閲覧)GBP2,499 ⇒換算¥369,852見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、全身性エリテマトーデス(SLE)治療薬の世界市場について調査・分析し、全身性エリテマトーデス(SLE)治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・全身性エリテマトーデス(SLE)治療薬の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・全身性エリテマトーデス(SLE)治療薬の世界市場:セグメント別市場分析
・全身性エリテマトーデス(SLE)治療薬の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Systemic Lupus Erythematosus – our new study reveals trends, R&D progress, and predicted revenues
Where is the SLE market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 152-page report provides 114 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing SLE market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are forecasts for 7 Products, 3 Molecule Types and 4 Pharmacological Classes

Systemic Lupus Erythematosus Market Forecasts to 2027, By Product
• Atacicept
• Benlysta
• Anifrolumab
• Lulizumab
• Bisibimod
• CellCept
• Prograf

Systemic Lupus Erythematosus Market Forecasts to 2027, By Molecule Type
• Small Molecules
• Monoclonal Antibodies
• Recombinant Proteins

Systemic Lupus Erythematosus Market Forecasts to 2027, By Pharmacological Class
• B-Cell Targeting Therapies
• Interferon Receptor Antagonists
• CD Antagonist Therapies
• Other Therapies for SLE

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 2 regional and 9 leading national markets:
• Regional Markets:
• LATAM (including Brazil)
• Asia Pacific

• National Markets:
• The US
• Canada
• Germany
• France
• The UK
• Italy
• Spain
• Japan
• China

The report also includes profiles and forecasts for some of the leading companies in the Systemic Lupus Erythematosus market, with a focus on the SLE segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that the developing markets, China in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market.

Leading companies and the potential for market growth
Overall world revenue for SLE will surpass $570m in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing prevalence of autoimmune disease, and increasing ageing population will increase sales to 2027.

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the SLE Market report helps you
In summary, our 152-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the world Systemic Lupus Erythematosus market and 3 different segmentations, with forecasts for 7 Products, 3 Molecule Types and 4 Pharmacological Classes – discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2027 for 2 regional markets and 9 of the leading national markets – LATAM (Including Brazil), APAC, US, Canada, Germany, UK, France, Italy, Spain, Japan, China,
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Systemic Lupus Erythematosus market and leading companies. You will find data, trends and predictions.

Get our report today The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027: Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class (B-Cell Targeting, Interferon Receptor Antagonists, CD Antagonists, Other) and Geography. Avoid missing out – get our report now.

【レポートの目次】

1. Report Overview
1.1 Systemic Lupus Erythematosus (SLE) Market Definition
1.2 Methodology
1.2.1 Primary Research
1.2.2 Secondary Research
1.2.3 Market Evaluation & Forecasting Methodology
1.3 Systemic Lupus Erythematosus (SLE) Report Structure
1.4 Why You Should Read This Report
1.5 How this Report Delivers
1.6 Key Questions Answered by This Analytical Report Include:
1.7 Who is This Report For?
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Systemic Lupus Erythematosus
2.1 Aetiology
2.2 Pathophysiology
2.3 Constitutional
2.4 Prognosis
2.5 Symptoms
2.6 Diagnosis
2.7 Assessing the Health Status of SLE patients
2.8 Current Treatment Options
2.9 Unmet Needs

3. Epidemiology
3.1 Prevalence
3.2 Incidence Rates (New Cases/Year)
3.3 Mortality
3.4 Hospitalizations
3.5 Ambulatory Care
3.6 Costs
3.7 Impact on Health-Related Quality of Life (HRQOL)

4. Systemic Lupus Erythematosus Market Forecast 2017-2027
4.1 Total population in US, EU, Japan and China
4.2 Systemic Lupus Erythematosus Prevalence Rate in US, EU, Japan and China
4.3 Diagnosed Systemic Lupus Erythematosus Population in US, EU, Japan and China
4.4 Systemic Lupus Erythematosus Drug Treated Patients in US, EU, Japan and China
4.5 Pricing Trends of the Market
4.6 Atacicept Sales Forecast 2017-2027
4.7 Benlysta Sales Forecast 2017-2027
4.8 Anifrolumab Sales Forecast 2017-2027
4.9 Lulizumab Sales Forecast 2017-2027
4.10 Bisibimod Sales Forecast 2017-2027
4.11 CellCept Sales Forecast 2017-2027
4.12 Prograf Sales Forecast 2017-2027
4.13 All Key SLE Therapies Sales

5. Product Profiles
5.1 Anifrolumab (AstraZeneca)
5.2 Atacicept (Merck)
5.3 Baricitinib (Eli Lilly)
5.4 Benlysta (GlaxoSmithKline)
5.5 Blisibimod (Anthera)
5.6 Lupuzor (ImmuPharma)

6. SLE Market Forecast By Molecule Type 2017-2027
6.1 Small Molecules Sales Forecast 2017-2027
6.2 Monoclonal Antibodies Sales Forecast 2017-2027
6.3 Recombinant Proteins Sales Forecast 2017-2027
6.4 Comparative Sales Analysis
6.5 Market Share – By Molecule Type

7. SLE Market Forecast by Pharmacological Class 2017-2027
7.1 B-Cell Targeting Therapies Sales Forecast 2017-2027
7.2 Interferon Receptor Antagonist Sales Forecast 2017-2027
7.3 CD Antagonist Therapies Sales Forecast 2017-2027
7.4 Other Therapies for SLE
7.5 Market Share – By Pharmacological Class Sales
7.6 Market Share – By Pharmacological Class Sales
7.7 Comparative analysis – Sales by Pharmacological Class Sales

8. Leading National Markets in the Systemic Lupus Erythematosus Market
8.1 US SLE Sales Forecast 2017-2027
8.2 Japan SLE Sales Forecast 2017-2027
8.3 China SLE Sales Forecast 2017-2027
8.4 LATAM (Including Brazil) SLE Sales Forecast 2017-2027
8.5 UK SLE Sales Forecast 2017-2027
8.6 France SLE Sales Forecast 2017-2027
8.7 Germany SLE Sales Forecast 2017-2027
8.8 Italy SLE Sales Forecast 2017-2027
8.9 Spain SLE Sales Forecast 2017-2027
8.10 Canada SLE Sales Forecast 2017-2027
8.11 APAC SLE Sales Forecast 2017-2027
8.12 Comparative analysis – EU Sales
8.13 Market Share – By EU Countries Sales
8.14 Market Share – By EU Countries Sales
8.15 Comparative analysis – US and EU Sales
8.16 Comparative analysis – China and Japan Sales
8.17 Comparative analysis – APAC and LATAM Sales
8.18 Comparative analysis – Key Market Sales

9. Product Launch timelines
9.1 Timeline of USA Launches
9.2 Timeline of EU Launches
9.3 Timeline of Japan Launches

10. Company Profiles
10.1 Anthera Company Profile
10.1.1 Anthera Company Overview
10.1.2 Anthera Projects Overview
10.1.3 Anthera Recent Deals
10.2 GSK Company Profile
10.2.1 GSK Company Overview
10.2.2 GSK Projects Overview
10.2.3 GSK Recent Deals
10.3 ImmuPharma Company Profile
10.3.1 ImmuPharma Company Overview
10.3.2 ImmuPharma Projects Overview
10.3.3 ImmuPharma Recent Deals
10.4 Merck Company Profile
10.4.1 Merck KGaA Company Overview
10.4.2 Merck Projects Overview
10.4.3 Merck Recent Deals
10.5 AstraZeneca Company Profile
10.5.1 AstraZeneca Company Overview
10.5.2 AstraZeneca Projects Overview
10.5.3 AstraZeneca Recent Deals
10.6 Eli Lilly Company Profile
10.6.1 Eli Lilly Company Overview
10.6.2 Eli Lilly Projects Overview
10.6.3 Eli Lilly Recent Deals
10.7 Other SLE companies

11. Qualitative Analysis of the Systemic Lupus Erythematosus Market
11.1 Strengths of the Systemic Lupus Erythematosus Market
11.2 Weakness of the Systemic Lupus Erythematosus Market
11.3 Opportunities for the Systemic Lupus Erythematosus Market
11.4 Threats for the Systemic Lupus Erythematosus Market
11.5 Political Factors Influencing the Systemic Lupus Erythematosus Market
11.6 Economical Factors Influencing the Systemic Lupus Erythematosus Market
11.7 Social Factors Influencing the Systemic Lupus Erythematosus Market
11.8 Technological Factors influencing the Systemic Lupus Erythematosus market

12. Key Findings and Report Conclusion
12.1 Cost of Therapies in Systemic Lupus Erythematosus
12.2 Geographical Trends of Systemic Lupus Erythematosus Market
12.3 Future of the Systemic Lupus Erythematosus Market

13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

List of Tables
Table 2.1 Diagnostic Tests for Systemic Lupus Erythematosus
Table 2.1 Diagnostic Tests for Systemic Lupus Erythematosus (continued)
Table 2.1 Diagnostic Tests for Systemic Lupus Erythematosus (continued)
Table 4.1 Total Country Population Forecast (in millions)
Table 4.2 Overall Systemic Lupus Erythematosus Prevalence Rate (per 100k population)
Table 4.3 Diagnosed Systemic Lupus Erythematosus Population (‘000)
Table 4.4 Systemic Lupus Erythematosus Drug Treated Patients
Table 4.5 Atacicept Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.7 Benlysta Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.8 Anifrolumab Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.9 Lulizumab Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.10 Bisibimod Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.11 CellCept Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.12 Prograf Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 4.13 All Key SLE Therapies Market Forecast: Revenues ($m) 2017-2027
Table 6.1 Small Molecules Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 6.2 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 6.3 Recombinant Proteins Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 6.4 Comparative analysis Market Forecast: Revenues ($m) 2017-2027
Table 6.5 Market Share – By Molecule Type Revenues ($m) 2022
Table 6.6 Market Share – By Molecule Type Revenues ($m) 2027
Table 7.1 B- Cell Targeting Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 7.2 Interferon Receptor Antagonist Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 7.3. CD Antagonist Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 7.4 Other Therapies in SLE Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 7.5 Market Share – By Pharmacological Class Revenues ($m) 2022
Table 7.6 Market Share – By Pharmacological Class Revenues ($m) 2027
Table 7.7 Comparative analysis – Sales by Pharmacological Class Revenues ($m) 2017-2027
Table 8.1 US SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.2 Japan SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.3 China SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.4 LATAM (Including Brazil) SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.5 UK SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.6 France SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.7 Germany SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.8 Italy SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.9 Spain SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.10 Canada SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.11 APAC SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
Table 8.12 Comparative analysis – EU-5 Revenues ($m) 2017-2027
Table 8.13 Market Share – By EU-5 Countries Revenues ($m) 2022
Table 8.15 Comparative analysis – US and EU-5 Revenues ($m) 2017-2027
Table 8.16 Comparative analysis – China and Japan Revenues ($m) 2017-2027
Table 8.17 Comparative analysis – APAC and LATAM Revenues ($m) 2017-2027
Table 8.18 Comparative analysis – Key Market Revenues ($m)2017-2027
Table 9.1 Timeline of USA Launches
Table 9.2 Timeline of EU Launches
Table 9.3 Timeline of Japan Launches
Table 10.1 Anthera Company Overview
Table 10.2 Anthera Key licensing deals
Table 10.3 GSK Company Overview
Table 10.4 GSK Key Licensing deals
Table 10.5 ImmuPharma Company Overview
Table 10.6 ImmuPharma Licensing deal
Table 10.7 Merck Company Overview
Table 10.8 Merck Key Licensing deals
Table 10.9 AstraZeneca Company Overview
Table 10.10 AstraZeneca Key licensing deals
Table 10.11 Eli Lilly Company Overview
Table 10.12 Eli Lilly Key licensing deals
Table 10.13 Other companies involved in the SLE market
Table 10.13 Other companies involved in the SLE market (continued)
Table 11.1 Strengths and Weakness of the Systemic Lupus Erythematosus Market
Table 11.2 Opportunities and Threats for the Systemic Lupus Erythematosus Market
Table 11.3 Political, Economical, Social and technological Factors influencing Systemic Lupus Erythematosus Market

List of Figures
Figure 4.1 Atacicept Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.2 Benlysta Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.3 Anifrolumab Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.4 Lulizumab Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.5 Bisibimod Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.6 CellCept Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.7 Prograf Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 4.8 All Key SLE Therapies Sales 2017-2027
Figure 6.1 Small Molecules Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 6.2 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 6.3 Recombinant Proteins Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 6.4 Comparative analysis Sales 2017-2027
Figure 6.5 Market Share – By Molecule Type Sales 2022
Figure 6.6 Market Share – By Molecule Type Sales 2027
Figure 7.1 B- Cell Targeting Therapies Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 7.2 Interferon Receptor Antagonist Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 7.3 CD Antagonist Therapies Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 7.4 Other Therapies in SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 7.5 Market Share – By Pharmacological Class Sales 2022
Figure 7.6 Market Share – By Pharmacological Class Sales 2027
Figure 7.7 Comparative analysis – Sales by Pharmacological Class Sales 2017-2027
Figure 8.1 US SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.2 Japan SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.3 China SLE Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.4 LATAM (Including Brazil) SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.5 UK SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.6 France SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.7 Germany SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.8 Italy SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.9 Spain SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.10 Canada SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.11 APAC SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
Figure 8.12 Comparative analysis – EU-5 Sales 2017-2027
Figure 8.13 Market Share – By EU-5 Countries Sales 2022
Figure 8.14 Market Share – By EU-5 Countries Sales 2027
Figure 8.15 Comparative analysis – US and EU-5 Sales 2017-2027
Figure 8.16 Comparative analysis – China and Japan Sales 2017-2027
Figure 8.17 Comparative analysis – APAC and LATAM Sales 2017-2027
Figure 8.18 Comparative analysis – Key Market Sales 2017-2027
Figure 10.1 Anthera project overview by development stage
Figure 10.2 Anthera project overview by Therapeutic area
Figure 10.3 GSK project overview by development stage
Figure 10.4 GSK project overview by Therapeutic area
Figure 10.5 ImmuPharma project overview by development stage
Figure 10.6 Immupharma project overview by Therapeutic area
Figure 10.7 Merck project overview by development stage
Figure 10.8 Merck project overview by Therapeutic area
Figure 10.9 AstraZeneca project overview by development stage
Figure 10.10 AstraZeneca project overview by Therapeutic area
Figure 10.11 Eli Lilly project overview by development stage
Figure 10.12 Eli Lilly project overview by Therapeutic area

【レポートのキーワード】

全身性エリテマトーデス、全身性エリテマトーデス治療薬、医薬品

★調査レポート[全身性エリテマトーデス(SLE)治療薬の世界市場予測] ( The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027 / VGAIN705043) 販売に関する免責事項
[全身性エリテマトーデス(SLE)治療薬の世界市場予測] ( The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027 / VGAIN705043) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆